© 2026 Forbes Digital Marketing Inc (FDMI). Forbes Advisor is operated by FDMI and is not controlled by Forbes Media LLC.
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...
The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, ...
© 2026 Forbes Digital Marketing Inc (FDMI). Forbes Advisor is operated by FDMI and is not controlled by Forbes Media LLC.
Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...
Conditional survival is the probability that a patient with a given disease will survive an additional number of years based on the fact that he or she has already survived a specific number of years.
SLL, also known as Studio LuluLala, announced a brand-new list of releases slated for the second half of the year and picked "popular appeal" as the keyword for its content in a press event Thursday. ...
Thursday 30 April 2026 1 EUR = 24598 SLL 24456 24601 EUR SLL rate for 30/04/2026 Wednesday 29 April 2026 1 EUR = 24488 SLL 24487 24560 EUR SLL rate for 29/04/2026 Tuesday 28 April 2026 1 EUR = 24568 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results